Reaction
Tumour Rupture reporting signals
As of the last recalculation, Tumour Rupture appears in 546 FAERS reports alongside 8 co-occurring drug terms. The strongest observed disproportionality signal is SORAFENIB (PRR 70.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sorafenib | 36 | 70.7 | 70.8 |
| Atezolizumab | 58 | 63.6 | 63.7 |
| Regorafenib | 14 | 47.2 | 47.2 |
| Lenvatinib | 36 | 44.7 | 44.8 |
| Sunitinib Malate | 34 | 35.1 | 35.1 |
| Bevacizumab | 73 | 25.8 | 25.8 |
| Durvalumab | 12 | 23.0 | 23.0 |
| Pazopanib Hydrochloride | 11 | 15.8 | 15.8 |